Evidence map›Paper›PMID 37146715›Full record

ArticleCellular and molecular gastroenterology and hepatology2023

Identification of a Transmembrane Protein Involved in Shear Stress Signaling and Hepatocarcinogenesis After a Sustained Virological Response to Hepatitis C Virus.

Masashi Nishikawa, Hikari Okada, Kazunori Kawaguchi, Tetsuro Shimakami, Kouki Nio, Kuniaki Arai, Tatsuya Yamashita, Motoko Sasaki, Shuichi Kaneko, Taro Yamashita and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Memories of Stress: The Imprinted Cancer Risk After HCV Cure.Cellular and molecular gastroenterology and hepatology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masashi NishikawaDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan; Department of Gastroenterology, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan.
Hikari OkadaDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kazunori KawaguchiDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Tetsuro ShimakamiDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kouki NioDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kuniaki AraiDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Tatsuya YamashitaDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Motoko SasakiDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Shuichi KanekoDepartment of Information-Based Medicine Development, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Taro YamashitaDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Masao HondaDepartment of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan; Department of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Electronic address: mhonda@m-kanazawa.jp.
Kanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThe risk of hepatocellular carcinoma (HCC) remains after achieving a sustained virological response (SVR) in patients with chronic hepatitis C (CHC). Epigenetic abnormalities might be key regulators in the development of HCC. This study aimed to identify the genes involved in hepatocarcinogenesis after an SVR.

methodsDNA methylation in liver tissue was compared between 21 CHC patients without HCC and 28 CHC patients with HCC, all of whom had achieved an SVR. Additional comparisons with 23 CHC patients before treatment and 10 normal livers were performed. The characteristics of a newly identified gene were explored in vitro and in vivo.

resultsWe found that the transmembrane protein no. 164 (TMEM164) gene was demethylated by hepatitis C virus infection and HCC development after achieving an SVR. TMEM164 was expressed mainly in endothelial cells, alpha smooth muscle actin-positive cells, and some capillarized liver sinusoidal endothelial cells. TMEM164 expression was significantly correlated with liver fibrosis and relapse-free survival in HCC patients. TMEM164 was induced by shear stress, interacted with GRP78/BiP, accelerated ATF6 (activating transcription factor 6)-mediated endoplasmic reticulum (ER) stress signaling, and activated interleukin-6/STAT3 (signal transducer and activator of transcription 3) signaling in the TMNK1 liver endothelial cell line. Therefore, we termed TMEM164 "shear stress-induced transmembrane protein associated with ER stress signaling" (SHERMER). SHERMER knockout mice were protected against CCL4-induced liver fibrosis. SHERMER overexpression in TMNK1 cells accelerated HCC growth in a xenograft model.

conclusionsWe identified a new transmembrane protein, SHERMER, in CHC patients with HCC after achieving an SVR. SHERMER was induced by shear stress and accelerated ATF6-mediated ER stress signaling in endothelial cells. Thus, SHERMER is a novel endothelial marker associated with liver fibrosis, hepatocarcinogenesis, and progression of HCC.

Indexed as

Carcinoma, HepatocellularHepatitis CLiver NeoplasmsAnimalsAntiviral AgentsEndothelial CellsHepacivirusHumansIncidenceLiver CirrhosisMiceAntiviral AgentsCarcinogenesisEndothelial CellsEpigenomeHCCLiver Cirrhosis

Identifiers

PMID37146715
PMCPMC10394272
OpenAlexW4367857102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.